Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 1.00 |
| ▸ | ACACA | Q13085 | 13/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045105 | 1.00 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16080656 | 1.00 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL12479480 | 0.88 | ACACB (0.79) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16080655 | 0.88 | ACACB (1.00) | ACACBACACANTRK1FLT3GSK3B | |
| SCHEMBL16044190 | 0.88 | ACACB (1.00) | ACACBACACANTRK1FLT3GSK3B | |
| SCHEMBL16044188 | 0.88 | ACACB (1.00) | ACACBACACANTRK1FLT3GSK3B | |
| SCHEMBL16042150 | 0.88 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16042148 | 0.88 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16080658 | 0.88 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 | |
| SCHEMBL16042043 | 0.87 | ACACB (1.00) | ACACBACACADAPK3NTRK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278925-B2 | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-20140275199-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275199-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | MALT1, UGT1A3, BMI1 | ACACB 1121/4885ACACA 1826/4885DAPK3 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.